Kumho HT's candidate product for cancer immunotherapy demonstrated drug tolerance and effectiveness in human-subject clinical trials. At the European Society for Medical Oncology (ESMO) Asia Congress 2024, held for three days from December 6, the Phase 1 clinical trial result of Kumho HT's DNP-002, a new anticancer drug, has been unveiled. Kumho HT anticipates collaboration with global pharmaceutical companies based on the results from the Phase 1 clinical trial.

In 2021, Kumho HT, an automotive electronics company, acquired the antibody drug developer DiNonA, officially making an entry into the biotechnology sector. The company's largest shareholder, S-MAC, aims to secure a new revenue stream through this